definiens: within the meaning of thePrivate Securities Litigation Reform Act of 1995, regarding, among other things, REGENXBIO ’s research, development and regulatory plans in connection with its NAVTechnology Platform and gene therapy treatments . Such forward - looking statements arebased on current expectations and involve inherent risks and uncertainties, includingfactors that could cause actual results to differ materially from those projected by suchforward - looking statements . All of REGENXBIO ’s development timelines could besubject to adjustment depending on recruitment rate, regulatory agency review and otherfactors that could delay the initiation and completion of clinical trials . Meaningful factorswhich could cause actual results to differ include, but are not limited to, the timing ofenrollment, commencement and completion of REGENXBIO ’s clinical trials ; the timingand success of preclinical studies and clinical trials conducted by REGENXBIO and itsdevelopment partners ; the ability to obtain and maintain regulatory approval ofREGENXBIO ’s product candidates, and the labeling for any approved products ; thescope, progress, expansion, and costs of developing and commercializingREGENXBIO ’s product candidates ; REGENXBIO ’s ability to establish and maintaindevelopment partnerships ; REGENXBIO ’s expenses and revenue ; regulatorydevelopments in the United States and foreign countries ; the sufficiency ofREGENXBIO ’s cash resources and needs for additional financing ; and other factorsdiscussed in the and sections of REGENXBIO ’s AnnualReport on Form 10 - K for the year ended December 31, 2016 and Quarterly Report onForm 10 - Q for the quarter ended March 31, 2017, which are on file with the Securitiesand Exchange Commission ( SEC ) and available at www.sec.gov . In addition to the risksdescribed above and in REGENXBIO ’s filings with the SEC, other unknown orunpredictable factors also could affect REGENXBIO ’s results . There can be noassurance that the actual results or developments anticipated by REGENXBIO will berealized or, even if substantially realized, that they will * * * * CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION . CONFIDENTIALTREATMENT HAS BEEN REQUESTED WITHRESPECT TO THE OMITTED PORTIONS